Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aronex Atragen

Executive Summary

Injectable tretinoin liposome receives "non-approvable" letter because clinical trials did not establish an identifiable population of acute promyelocytic leukemia patients requiring a non-oral formulation, company says. Aronex needed to show efficacy in a population in which I.V. administration is required because of the orphan exclusivity of Roche's oral tretinoin Vesanoid. Aronex plans to study Atragen for non-Hodgkin's lymphoma in a Phase III 200-patient trial. The company will lay off most its 85 employees, retaining only clinical and regulatory personnel
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel